Brown, Lisle/Cummings’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$188K Hold
1,349
0.05% 220
2025
Q4
$166K Sell
1,349
-150
-10% -$18.2K 0.04% 230
2025
Q3
$166K Hold
1,499
0.04% 226
2025
Q2
$166K Sell
1,499
-125
-8% -$13.3K 0.04% 230
2025
Q1
$182K Buy
1,624
+49
+3% +$5.06K 0.05% 208
2024
Q4
$145K Sell
1,575
-500
-24% -$45K 0.04% 234
2024
Q3
$174K Sell
2,075
-766
-27% -$58.4K 0.05% 219
2024
Q2
$195K Buy
2,841
+1
+0% +$67 0.06% 202
2024
Q1
$208K Sell
2,840
-224
-7% -$17.2K 0.07% 193
2023
Q4
$248K Sell
3,064
-149
-5% -$11.6K 0.09% 178
2023
Q3
$241K Buy
3,213
+77
+2% +$5.92K 0.11% 166
2023
Q2
$242K Sell
3,136
-1,349
-30% -$108K 0.11% 165
2023
Q1
$372K Sell
4,485
-2,019
-31% -$167K 0.19% 122
2022
Q4
$558K Buy
6,504
+181
+3% +$14.3K 0.3% 86
2022
Q3
$390K Sell
6,323
-116
-2% -$7.32K 0.23% 105
2022
Q2
$398K Sell
6,439
-417
-6% -$25.8K 0.22% 106
2022
Q1
$408K Buy
6,856
+1,065
+18% +$68.1K 0.2% 114
2021
Q4
$420K Buy
+5,791
New +$399K 0.21% 109

Other funds holding GILD

Brown, Lisle/Cummings's GILD Position: Q1 2026 in Review

Brown, Lisle/Cummings held its Gilead Sciences (GILD) position steady in Q1 2026 at 1,349 shares worth $188K. The position accounts for 0.05% of the portfolio, ranked #220.

Brown, Lisle/Cummings first reported a position in GILD in Q4 2021 and has held it in 18 quarters since. The position peaked at $558K in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Brown, Lisle/Cummings held 1,349 shares of Gilead Sciences worth $188K as of Q1 2026.
  • Brown, Lisle/Cummings left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.05% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #220 holding.
  • Brown, Lisle/Cummings first reported a position in Gilead Sciences in Q4 2021 and has held it in 18 quarters since.
  • Brown, Lisle/Cummings's Gilead Sciences position peaked at $558K in Q4 2022.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.